TickerFacts.

Structure Therapeutics Inc. (GPCR): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$222.20M
Year ended 2025-12-31
-$220.29M
Trailing 12 months to 2026-06-30
2022-12-31: -$46.12M2023-12-31: -$79.49M2024-12-31: -$116.64M2025-12-31: -$222.20M-$222.20M
2022-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$222.20Mn/m2026-02-26, From 2025-01-01
2024-12-31-$116.64Mn/m2026-02-26, From 2024-01-01
2023-12-31-$79.49Mn/m2026-02-26, From 2023-01-01
2022-12-31-$46.12Mn/a2024-03-08, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Structure Therapeutics Inc. (GPCR)2025-12-31-$222.20Mn/m
Acadia Pharmaceuticals Inc (ACAD)2025-12-31$109.84M-30.4%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$49.36M-49.1%
Amphastar Pharmaceuticals, Inc. (AMPH)2025-12-31$156.12M-26.8%
Innoviva, Inc. (INVA)2025-12-31$196.93M+4.4%
Ultragenyx Pharmaceutical Inc. (RARE)2025-12-31-$466.00Mn/m
Collegium Pharmaceutical, Inc (COLL)2025-12-31$329.32M+60.7%
Phibro Animal Health Corp (PAHC)2026-06-30$68.95M-13.9%
Supernus Pharmaceuticals, Inc. (SUPN)2025-12-31$47.33M-72.5%

Compare GPCR, ACAD, LGND, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗